Ardent Health (ARDT) to Announce Earnings on Tuesday

Ardent Health (NYSE:ARDT) is expected to be issuing its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect the company to post earnings of $0.1817 per share and revenue of $1.5897 billion for the quarter. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Ardent Health (NYSE:ARDT) last posted its earnings results on Tuesday, May 5th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $0.10. The company had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Ardent Health had a net margin of 2.09% and a return on equity of 13.85%. On average, analysts expect Ardent Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Ardent Health Trading Down 0.0%

Shares of ARDT stock opened at $10.67 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.00. The firm has a market cap of $1.53 billion, a PE ratio of 11.23, a price-to-earnings-growth ratio of 2.51 and a beta of 0.70. The company has a 50-day moving average of $9.79 and a two-hundred day moving average of $9.42. Ardent Health has a 1-year low of $7.71 and a 1-year high of $15.48.

Insider Buying and Selling at Ardent Health

In other Ardent Health news, CFO Alfred Lumsdaine bought 10,000 shares of the business’s stock in a transaction that occurred on Friday, June 5th. The shares were purchased at an average cost of $8.81 per share, with a total value of $88,100.00. Following the purchase, the chief financial officer directly owned 329,183 shares in the company, valued at approximately $2,900,102.23. This represents a 3.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 1.90% of the company’s stock.

Hedge Funds Weigh In On Ardent Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ARDT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Ardent Health by 103.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,104 shares of the company’s stock worth $194,000 after acquiring an additional 7,182 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Ardent Health by 1,684.9% in the first quarter. Goldman Sachs Group Inc. now owns 767,862 shares of the company’s stock valued at $10,558,000 after acquiring an additional 724,841 shares in the last quarter. Jane Street Group LLC boosted its holdings in Ardent Health by 235.1% in the first quarter. Jane Street Group LLC now owns 57,468 shares of the company’s stock valued at $790,000 after purchasing an additional 40,318 shares during the period. Acadian Asset Management LLC boosted its holdings in Ardent Health by 574.9% in the first quarter. Acadian Asset Management LLC now owns 40,238 shares of the company’s stock valued at $550,000 after purchasing an additional 34,276 shares during the period. Finally, Geode Capital Management LLC grew its stake in Ardent Health by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock worth $3,918,000 after purchasing an additional 1,769 shares in the last quarter.

Analysts Set New Price Targets

Several equities analysts have recently commented on ARDT shares. Truist Financial decreased their price objective on shares of Ardent Health from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Weiss Ratings reissued a “sell (d+)” rating on shares of Ardent Health in a research report on Friday, June 12th. UBS Group upped their price target on Ardent Health from $13.00 to $13.50 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Royal Bank Of Canada lowered their price target on Ardent Health from $13.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, July 9th. Finally, Wall Street Zen downgraded Ardent Health from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Seven investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $14.04.

About Ardent Health

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company’s integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.